Uncategorized

Something amiss …..

Last Friday Tandem stock came under a short attack with short sellers posting news of a death of a patient who was using a Tandem pump. Now before we go any further a few words about the FDA adverse event reporting system, which is vastly outdated, subject to wide interpretation, abused constantly yet the only system we have. Medical device companies are given an incredible amount of latitude as what...

Knew this was coming

If there is one thing, we can count on its Medtronic being consistent. The company knows they are in a boatload of trouble with the Control IQ coming from Tandem. They know the way cool whiz bang 670G as way cool and whiz bang as it is isn’t getting much love from the insulin pump community. They also know it will be some time before any of their new whiz...

Just when it looks wacky it gets ….

Things certainly are wacky these days. The Fighting Illini football team has won four Big Ten games in a row becoming bowl eligible. Our beloved Chicago Bears finally won a football game. Livongo seems to have found some life, Dexcom is blazing hot, Insulet is on fire while Tandem and Abbott continue to wait for the FDA to do its thing. One of the things we wonder about given the competitive...

What to make of all this?

As much as we aren’t ones for explanations lots of people like to know the why’s and wherefores. No they cannot be content that their Dexcom, Tandem or Insulet shares have skyrocketed this year, they must know why they have skyrocketed. Yes, this backward-looking Monday morning quarterbacking doesn’t do much, but it seems to comfort many. Now we’d sure like to be nice and indulge these people or we could...

Is this getting out of control?

One of the most difficult things to predict is when a stock hits a ceiling. There are all sorts of technical and financial measures investors use to judge this yet even with these advanced mathematics stock levels often defy any logical valuations. Given what’s going in the diabetes device space we wonder if we are hitting an inflection point. Consider the following; Insulet market cap is approaching $10 BILLION Dexcom up some...

As Good as it gets and The Sting

Yesterday we had both Dexcom and Livongo reporting and given our fondness for movies we’d title the Dexcom’s results As Good as it gets while Livongo reminds of us of The Sting. Let’s start with Dexcom who noted in their earnings release; “Revenue grew 49% versus the same quarter of the prior year to $396.3 million U.S. revenue growth of 53% and international revenue growth of 36% GAAP operating income of $56.0 million...

Killing It

There is no other way to characterize Insulet’s results as they are flat out killing it. Check out these facts from the press release; “Third quarter revenue of $192.1 million, up 27%, compared to revenue of $151.1 million in the prior year, exceeds guidance of $174 to $181 million For the year ending December 31, 2019, the Company is raising its revenue guidance to a range of $722 to $730 million, representing...

News abounds in CGMland

The last thing any company needs especially one that is trying to establish itself in the crowded and growing CGM market is a recall. Unfortunately that’s exactly what happened with Senseonics. Per a story posted on the Mobihealthnews site; “The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and distributors in the...

Hurry up and wait

First things first as it’s time to get rid of classical music while we wait for a call to begin. How about some country or hip hop? Anyway the Tandem results and call all came down to one thing and one thing only – Tandem and the entire diabetes community continues to wait for the FDA to do their thing and approve the Control IQ already. Unfortunately neither the company...

Betting the farm

We knew going in that the Friday Novo Nordisk earnings report and corresponding call would be all about GLP-1’ s and that’s exactly what we got. Before we go into a more detailed analysis things for Novo can be summed up this way- the insulin market has fully commoditized making volume growth critical as prices will continue to contract – the battleground for making money has become the expanding GLP-1...